# A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SHR-3032 in Healthy Subjects

> **NCT06090799** · PHASE1 · COMPLETED · sponsor: **Guangdong Hengrui Pharmaceutical Co., Ltd** · enrollment: 6 (actual)

## Conditions studied

- Prevention of Graft Rejection After Organ Transplantation

## Interventions

- **DRUG:** SHR-3032
- **DRUG:** SHR-3032 Placebo

## Key facts

- **NCT ID:** NCT06090799
- **Lead sponsor:** Guangdong Hengrui Pharmaceutical Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-11-29
- **Primary completion:** 2024-03-28
- **Final completion:** 2024-04-08
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2024-10-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06090799

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06090799, "A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SHR-3032 in Healthy Subjects". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06090799. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*